The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
3don MSN
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...
The brain-computer interface technology personalizes therapy based on an individual’s brain activity.
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results